ISBN 10: 1484094522 / ISBN 13: 9781484094525
Gebraucht / Anzahl: 0
Bei weiteren Verkäufern erhältlich
Alle  Exemplare dieses Buches anzeigen

Über dieses Buch

Leider ist dieses Exemplar nicht mehr verfügbar. Wir haben Ihnen weitere Exemplare dieses Titels unten aufgelistet.

Beschreibung:

Brand New, Unread Copy in Perfect Condition. A+ Customer Service! Summary: Major depressive disorder (MDD) is common and costly. Over the course of a year, between 13.1 million and 14.2 million people will experience MDD. Approximately half of these people seek help for this condition, and only 20% of those receive adequate treatment. For those who do initiate treatment for their depression, approximately 50% will not adequately respond following acute-phase treatment; this refractory group has considerable clinical and research interest. Patients with only one prior treatment failure are sometimes included in this group, but patients with two or more prior treatment failures are a particularly important and poorly understood group and are considered to have treatment-resistant depression (TRD). Patients with TRD incur the highest direct and indirect medical costs among those with MDD. These costs increase with the severity of TRD. Treatment-resistant patients are twice as likely to be hospitalized, and their cost of hospitalization is more than six times the mean total costs of depressed patients who are not treatment resistant. Given the burden of TRD generally, the uncertain prognosis of the disorder, and the high costs of therapy, clinicians and patients need clear evidence to guide their treatment decisions. The choices are wide ranging, include both pharmacologic and nonpharmacologic interventions, and are fraught with incomplete, potentially even conflicting, evidence. Somatic treatments, which may involve use of a pharmacologic intervention or a device, are commonly considered for patients with TRD. Antidepressant medications, which are the most commonly used intervention, have decreasing efficacy for producing remission after patients have experienced two failures. Such drugs also often have side effects, sometimes minor but sometimes quite serious. For these reasons, clinicians often look for alternative strategies for their TRD patients. This review is intended to help various decisionmakers come to informed choices about the use of nonpharmacologic interventions for TRD in adults. Our principal goal is to summarize comparative data on the efficacy, effectiveness, and harms of electroconvulsive therapy, repetitive transcranial magnetic stimulation, vagus nerve stimulation, and cognitive behavioral therapy or interpersonal psychotherapy in patients with TRD. The following Key Questions are addressed: KQ1a. For adults with TRD, do nonpharmacologic interventions such as electroconvulsive therapy, repetitive transcranial magnetic stimulation, vagus nerve stimulation, or demonstrated effective psychotherapy differ in efficacy or effectiveness in treating acute-phase depressive symptoms (e.g., response and remission), whether as a single treatment or part of a combination treatment? KQ1b. How do these nonpharmacologic treatments compare with pharmacological treatments in efficacy or effectiveness in treating acute-phase depressive symptoms after two or more failed adequate trials? KQ2. For adults with TRD, do nonpharmacologic interventions differ in their efficacy or effectiveness for maintaining response or remission, whether as a single treatment or part of a combination treatment? KQ3. Do nonpharmacologic interventions differ in their efficacy or effectiveness for treating TRD as a function of particular symptom subtypes (e.g., catatonic or psychotic symptoms)? KQ4. For adults with TRD, do nonpharmacologic interventions differ in safety, adverse events, or adherence? Adverse effects of interest include but are not limited to amnesia, memory loss, headaches, and postoperative complications. KQ5. How do the efficacy, effectiveness, or harms of treatment with nonpharmacologic treatments for TRD differ for the following subpopulations: Elderly or very elderly patients; other demographic groups (defined by age, ethnic or racial groups, and sex)? Patients with medical comorbidities? KQ6. For adults with TRD, do nonpharmacolo. Buchnummer des Verkäufers

Über diesen Titel:

Bewertung (bereitgestellt von GoodReads):
0 durchschnittlich
(0 Bewertungen)

Inhaltsangabe: Major depressive disorder (MDD) is common and costly. Over the course of a year, between 13.1 million and 14.2 million people will experience MDD. Approximately half of these people seek help for this condition, and only 20% of those receive adequate treatment. For those who do initiate treatment for their depression, approximately 50% will not adequately respond following acute-phase treatment; this refractory group has considerable clinical and research interest. Patients with only one prior treatment failure are sometimes included in this group, but patients with two or more prior treatment failures are a particularly important and poorly understood group and are considered to have treatment-resistant depression (TRD). Patients with TRD incur the highest direct and indirect medical costs among those with MDD. These costs increase with the severity of TRD. Treatment-resistant patients are twice as likely to be hospitalized, and their cost of hospitalization is more than six times the mean total costs of depressed patients who are not treatment resistant. Given the burden of TRD generally, the uncertain prognosis of the disorder, and the high costs of therapy, clinicians and patients need clear evidence to guide their treatment decisions. The choices are wide ranging, include both pharmacologic and nonpharmacologic interventions, and are fraught with incomplete, potentially even conflicting, evidence. Somatic treatments, which may involve use of a pharmacologic intervention or a device, are commonly considered for patients with TRD. Antidepressant medications, which are the most commonly used intervention, have decreasing efficacy for producing remission after patients have experienced two failures. Such drugs also often have side effects, sometimes minor but sometimes quite serious. For these reasons, clinicians often look for alternative strategies for their TRD patients. This review is intended to help various decisionmakers come to informed choices about the use of nonpharmacologic interventions for TRD in adults. Our principal goal is to summarize comparative data on the efficacy, effectiveness, and harms of electroconvulsive therapy, repetitive transcranial magnetic stimulation, vagus nerve stimulation, and cognitive behavioral therapy or interpersonal psychotherapy in patients with TRD. The following Key Questions are addressed: KQ1a. For adults with TRD, do nonpharmacologic interventions such as electroconvulsive therapy, repetitive transcranial magnetic stimulation, vagus nerve stimulation, or demonstrated effective psychotherapy differ in efficacy or effectiveness in treating acute-phase depressive symptoms (e.g., response and remission), whether as a single treatment or part of a combination treatment? KQ1b. How do these nonpharmacologic treatments compare with pharmacological treatments in efficacy or effectiveness in treating acute-phase depressive symptoms after two or more failed adequate trials? KQ2. For adults with TRD, do nonpharmacologic interventions differ in their efficacy or effectiveness for maintaining response or remission, whether as a single treatment or part of a combination treatment? KQ3. Do nonpharmacologic interventions differ in their efficacy or effectiveness for treating TRD as a function of particular symptom subtypes (e.g., catatonic or psychotic symptoms)? KQ4. For adults with TRD, do nonpharmacologic interventions differ in safety, adverse events, or adherence? Adverse effects of interest include but are not limited to amnesia, memory loss, headaches, and postoperative complications. KQ5. How do the efficacy, effectiveness, or harms of treatment with nonpharmacologic treatments for TRD differ for the following subpopulations: Elderly or very elderly patients; other demographic groups (defined by age, ethnic or racial groups, and sex)? Patients with medical comorbidities? KQ6. For adults with TRD, do nonpharmacologic interventions differ in regard to other health-related outcomes?

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

Bibliografische Details

Zustand: New

Beste Suchergebnisse bei AbeBooks

1.

ISBN 10: 1484094522 ISBN 13: 9781484094525
Neu Anzahl: > 20
Print-on-Demand
Anbieter
BWB
(Valley Stream, NY, USA)
Bewertung
[?]

Buchbeschreibung Buchzustand: New. This item is Print on Demand - Depending on your location, this item may ship from the US or UK. Buchnummer des Verkäufers POD_9781484094525

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 64,31
Währung umrechnen

In den Warenkorb

Versand: Gratis
Von USA nach Deutschland
Versandziele, Kosten & Dauer

2.

Human Services, U. S. Department of Heal
ISBN 10: 1484094522 ISBN 13: 9781484094525
Neu Anzahl: > 20
Print-on-Demand
Anbieter
Books2Anywhere
(Fairford, GLOS, Vereinigtes Königreich)
Bewertung
[?]

Buchbeschreibung 2013. PAP. Buchzustand: New. New Book. Delivered from our UK warehouse in 3 to 5 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Buchnummer des Verkäufers I2-9781484094525

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 63,11
Währung umrechnen

In den Warenkorb

Versand: EUR 11,56
Von Vereinigtes Königreich nach Deutschland
Versandziele, Kosten & Dauer

3.

Human Services, U. S. Department of Heal
ISBN 10: 1484094522 ISBN 13: 9781484094525
Neu Anzahl: > 20
Print-on-Demand
Anbieter
PBShop
(Wood Dale, IL, USA)
Bewertung
[?]

Buchbeschreibung 2013. PAP. Buchzustand: New. New Book. Shipped from US within 10 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Buchnummer des Verkäufers I2-9781484094525

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 62,61
Währung umrechnen

In den Warenkorb

Versand: EUR 13,81
Von USA nach Deutschland
Versandziele, Kosten & Dauer

4.

Human Services, U. S. Department of Health and; and Quality, Agency for Healthcare Research
Verlag: CreateSpace Independent Publishing Platform
ISBN 10: 1484094522 ISBN 13: 9781484094525
Neu PAPERBACK Anzahl: > 20
Anbieter
Russell Books
(Victoria, BC, Kanada)
Bewertung
[?]

Buchbeschreibung CreateSpace Independent Publishing Platform. PAPERBACK. Buchzustand: New. 1484094522 Special order direct from the distributor. Buchnummer des Verkäufers ING9781484094525

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 66,14
Währung umrechnen

In den Warenkorb

Versand: EUR 27,62
Von Kanada nach Deutschland
Versandziele, Kosten & Dauer

5.

U S Department of Heal Human Services, Agency for Healthcare Resea And Quality
Verlag: Createspace, United States (2013)
ISBN 10: 1484094522 ISBN 13: 9781484094525
Neu Paperback Anzahl: 10
Print-on-Demand
Anbieter
The Book Depository
(London, Vereinigtes Königreich)
Bewertung
[?]

Buchbeschreibung Createspace, United States, 2013. Paperback. Buchzustand: New. 235 x 190 mm. Language: English . Brand New Book ***** Print on Demand *****.Major depressive disorder (MDD) is common and costly. Over the course of a year, between 13.1 million and 14.2 million people will experience MDD. Approximately half of these people seek help for this condition, and only 20 of those receive adequate treatment. For those who do initiate treatment for their depression, approximately 50 will not adequately respond following acute-phase treatment; this refractory group has considerable clinical and research interest. Patients with only one prior treatment failure are sometimes included in this group, but patients with two or more prior treatment failures are a particularly important and poorly understood group and are considered to have treatment-resistant depression (TRD). Patients with TRD incur the highest direct and indirect medical costs among those with MDD. These costs increase with the severity of TRD. Treatment-resistant patients are twice as likely to be hospitalized, and their cost of hospitalization is more than six times the mean total costs of depressed patients who are not treatment resistant. Given the burden of TRD generally, the uncertain prognosis of the disorder, and the high costs of therapy, clinicians and patients need clear evidence to guide their treatment decisions. The choices are wide ranging, include both pharmacologic and nonpharmacologic interventions, and are fraught with incomplete, potentially even conflicting, evidence. Somatic treatments, which may involve use of a pharmacologic intervention or a device, are commonly considered for patients with TRD. Antidepressant medications, which are the most commonly used intervention, have decreasing efficacy for producing remission after patients have experienced two failures. Such drugs also often have side effects, sometimes minor but sometimes quite serious. For these reasons, clinicians often look for alternative strategies for their TRD patients. This review is intended to help various decisionmakers come to informed choices about the use of nonpharmacologic interventions for TRD in adults. Our principal goal is to summarize comparative data on the efficacy, effectiveness, and harms of electroconvulsive therapy, repetitive transcranial magnetic stimulation, vagus nerve stimulation, and cognitive behavioral therapy or interpersonal psychotherapy in patients with TRD. The following Key Questions are addressed: KQ1a. For adults with TRD, do nonpharmacologic interventions such as electroconvulsive therapy, repetitive transcranial magnetic stimulation, vagus nerve stimulation, or demonstrated effective psychotherapy differ in efficacy or effectiveness in treating acute-phase depressive symptoms (e.g., response and remission), whether as a single treatment or part of a combination treatment? KQ1b. How do these nonpharmacologic treatments compare with pharmacological treatments in efficacy or effectiveness in treating acute-phase depressive symptoms after two or more failed adequate trials? KQ2. For adults with TRD, do nonpharmacologic interventions differ in their efficacy or effectiveness for maintaining response or remission, whether as a single treatment or part of a combination treatment? KQ3. Do nonpharmacologic interventions differ in their efficacy or effectiveness for treating TRD as a function of particular symptom subtypes (e.g., catatonic or psychotic symptoms)? KQ4. For adults with TRD, do nonpharmacologic interventions differ in safety, adverse events, or adherence? Adverse effects of interest include but are not limited to amnesia, memory loss, headaches, and postoperative complications. KQ5. How do the efficacy, effectiveness, or harms of treatment with nonpharmacologic treatments for TRD differ for the following subpopulations: Elderly or very elderly patients; other demographic groups (defined by age, ethnic or racial groups, and sex)? Patients with medical comorbidities? KQ6. For adults with TRD, do nonpharmacologic interventi. Buchnummer des Verkäufers APC9781484094525

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 79,27
Währung umrechnen

In den Warenkorb

Versand: Gratis
Von Vereinigtes Königreich nach Deutschland
Versandziele, Kosten & Dauer

6.

U S Department of Heal Human Services, Agency for Healthcare Resea And Quality
Verlag: Createspace, United States (2013)
ISBN 10: 1484094522 ISBN 13: 9781484094525
Neu Paperback Anzahl: 10
Print-on-Demand
Anbieter
The Book Depository US
(London, Vereinigtes Königreich)
Bewertung
[?]

Buchbeschreibung Createspace, United States, 2013. Paperback. Buchzustand: New. 235 x 190 mm. Language: English . Brand New Book ***** Print on Demand *****. Major depressive disorder (MDD) is common and costly. Over the course of a year, between 13.1 million and 14.2 million people will experience MDD. Approximately half of these people seek help for this condition, and only 20 of those receive adequate treatment. For those who do initiate treatment for their depression, approximately 50 will not adequately respond following acute-phase treatment; this refractory group has considerable clinical and research interest. Patients with only one prior treatment failure are sometimes included in this group, but patients with two or more prior treatment failures are a particularly important and poorly understood group and are considered to have treatment-resistant depression (TRD). Patients with TRD incur the highest direct and indirect medical costs among those with MDD. These costs increase with the severity of TRD. Treatment-resistant patients are twice as likely to be hospitalized, and their cost of hospitalization is more than six times the mean total costs of depressed patients who are not treatment resistant. Given the burden of TRD generally, the uncertain prognosis of the disorder, and the high costs of therapy, clinicians and patients need clear evidence to guide their treatment decisions. The choices are wide ranging, include both pharmacologic and nonpharmacologic interventions, and are fraught with incomplete, potentially even conflicting, evidence. Somatic treatments, which may involve use of a pharmacologic intervention or a device, are commonly considered for patients with TRD. Antidepressant medications, which are the most commonly used intervention, have decreasing efficacy for producing remission after patients have experienced two failures. Such drugs also often have side effects, sometimes minor but sometimes quite serious. For these reasons, clinicians often look for alternative strategies for their TRD patients. This review is intended to help various decisionmakers come to informed choices about the use of nonpharmacologic interventions for TRD in adults. Our principal goal is to summarize comparative data on the efficacy, effectiveness, and harms of electroconvulsive therapy, repetitive transcranial magnetic stimulation, vagus nerve stimulation, and cognitive behavioral therapy or interpersonal psychotherapy in patients with TRD. The following Key Questions are addressed: KQ1a. For adults with TRD, do nonpharmacologic interventions such as electroconvulsive therapy, repetitive transcranial magnetic stimulation, vagus nerve stimulation, or demonstrated effective psychotherapy differ in efficacy or effectiveness in treating acute-phase depressive symptoms (e.g., response and remission), whether as a single treatment or part of a combination treatment? KQ1b. How do these nonpharmacologic treatments compare with pharmacological treatments in efficacy or effectiveness in treating acute-phase depressive symptoms after two or more failed adequate trials? KQ2. For adults with TRD, do nonpharmacologic interventions differ in their efficacy or effectiveness for maintaining response or remission, whether as a single treatment or part of a combination treatment? KQ3. Do nonpharmacologic interventions differ in their efficacy or effectiveness for treating TRD as a function of particular symptom subtypes (e.g., catatonic or psychotic symptoms)? KQ4. For adults with TRD, do nonpharmacologic interventions differ in safety, adverse events, or adherence? Adverse effects of interest include but are not limited to amnesia, memory loss, headaches, and postoperative complications. KQ5. How do the efficacy, effectiveness, or harms of treatment with nonpharmacologic treatments for TRD differ for the following subpopulations: Elderly or very elderly patients; other demographic groups (defined by age, ethnic or racial groups, and sex)? Patients with medical comorbidities? KQ6. For adults with TRD, do nonpharmacologic intervent. Buchnummer des Verkäufers APC9781484094525

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 79,32
Währung umrechnen

In den Warenkorb

Versand: Gratis
Von Vereinigtes Königreich nach Deutschland
Versandziele, Kosten & Dauer

7.

U. S. Department of Health and Human Services
Verlag: CreateSpace Independent Publishing Platform
ISBN 10: 1484094522 ISBN 13: 9781484094525
Neu Paperback Anzahl: 20
Print-on-Demand
Anbieter
BuySomeBooks
(Las Vegas, NV, USA)
Bewertung
[?]

Buchbeschreibung CreateSpace Independent Publishing Platform. Paperback. Buchzustand: New. This item is printed on demand. Paperback. 828 pages. Dimensions: 9.2in. x 7.5in. x 1.9in.Major depressive disorder (MDD) is common and costly. Over the course of a year, between 13. 1 million and 14. 2 million people will experience MDD. Approximately half of these people seek help for this condition, and only 20 of those receive adequate treatment. For those who do initiate treatment for their depression, approximately 50 will not adequately respond following acute-phase treatment; this refractory group has considerable clinical and research interest. Patients with only one prior treatment failure are sometimes included in this group, but patients with two or more prior treatment failures are a particularly important and poorly understood group and are considered to have treatment-resistant depression (TRD). Patients with TRD incur the highest direct and indirect medical costs among those with MDD. These costs increase with the severity of TRD. Treatment-resistant patients are twice as likely to be hospitalized, and their cost of hospitalization is more than six times the mean total costs of depressed patients who are not treatment resistant. Given the burden of TRD generally, the uncertain prognosis of the disorder, and the high costs of therapy, clinicians and patients need clear evidence to guide their treatment decisions. The choices are wide ranging, include both pharmacologic and nonpharmacologic interventions, and are fraught with incomplete, potentially even conflicting, evidence. Somatic treatments, which may involve use of a pharmacologic intervention or a device, are commonly considered for patients with TRD. Antidepressant medications, which are the most commonly used intervention, have decreasing efficacy for producing remission after patients have experienced two failures. Such drugs also often have side effects, sometimes minor but sometimes quite serious. For these reasons, clinicians often look for alternative strategies for their TRD patients. This review is intended to help various decisionmakers come to informed choices about the use of nonpharmacologic interventions for TRD in adults. Our principal goal is to summarize comparative data on the efficacy, effectiveness, and harms of electroconvulsive therapy, repetitive transcranial magnetic stimulation, vagus nerve stimulation, and cognitive behavioral therapy or interpersonal psychotherapy in patients with TRD. The following Key Questions are addressed: KQ1a. For adults with TRD, do nonpharmacologic interventions such as electroconvulsive therapy, repetitive transcranial magnetic stimulation, vagus nerve stimulation, or demonstrated effective psychotherapy differ in efficacy or effectiveness in treating acute-phase depressive symptoms (e. g. , response and remission), whether as a single treatment or part of a combination treatment KQ1b. How do these nonpharmacologic treatments compare with pharmacological treatments in efficacy or effectiveness in treating acute-phase depressive symptoms after two or more failed adequate trials KQ2. For adults with TRD, do nonpharmacologic interventions differ in their efficacy or effectiveness for maintaining response or remission, whether as a single treatment or part of a combination treatment KQ3. Do nonpharmacologic interventions differ in their efficacy or effectiveness for treating TRD as a function of particular symptom subtypes (e. g. , catatonic or psychotic symptoms) KQ4. For adults with TRD, do nonpharmacologic interventions differ in safety, adverse events, or adherence Adverse effects of interest include but are not limited to amnesia, memory loss, headaches, and postoperative complications. KQ5. How do the efficacy, effectiveness, or harms of treatment with nonpharmacologic treatments for TRD differ for the following subpopulations: Elderly or very elderly patients; other demographic groups (defined by age, ethnic or racial groups, and sex) Patients with medical como This item ships from La Vergne,TN. Paperback. Buchnummer des Verkäufers 9781484094525

Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

Neu kaufen
EUR 79,38
Währung umrechnen

In den Warenkorb

Versand: EUR 11,92
Von USA nach Deutschland
Versandziele, Kosten & Dauer